Neurolytic Agents (Phenol, Alcohol) Market Analysis

Nerve Blocks Market to Reach USD 9.4 Billion by 2033 at 6.4% CAGR

Phenol and ethanol blocks for spasticity management and cancer pain neurolysis occupy a small but clinically distinct niche. A Phase 4 trial (nct:NCT07440173) comparing phenol neurolysis plus botulinum toxin versus botulinum toxin alone for post-stroke upper-limb spasticity is not yet recruiting but illustrates the continuing investigation of chemical neurolysis. Regulatory handling varies by jurisdiction; phenol for injection is not subject to standard NDA pathways in the U.S. but falls under USP compounding monograph requirements.